These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34878687)
1. BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019). Gedon J; Kehl A; Aupperle-Lellbach H; von Bomhard W; Schmidt JM Vet Comp Oncol; 2022 Jun; 20(2):449-457. PubMed ID: 34878687 [TBL] [Abstract][Full Text] [Related]
2. Effective detection of BRAF Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202 [TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs. Yamasaki H; Uematsu Y; Okano K; Ichikawa M; Tei M; Hirabayashi M; Uchida K; Ono K; Hirao H In Vitro Cell Dev Biol Anim; 2022 Dec; 58(10):898-911. PubMed ID: 36477686 [TBL] [Abstract][Full Text] [Related]
5. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption. Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639 [TBL] [Abstract][Full Text] [Related]
6. Coincidence of v-raf murine sarcoma viral oncogene homolog B mutation (V595E) with phosphorylated v-raf murine sarcoma viral oncogene homolog B in urothelial carcinoma in dogs. Yamasaki H; Uematsu Y; Hayashi Y; Yamashita M; Tei M; Uchida K; Ono K; Hirao H Can J Vet Res; 2022 Oct; 86(4):286-293. PubMed ID: 36211215 [TBL] [Abstract][Full Text] [Related]
7. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma]. Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168 [TBL] [Abstract][Full Text] [Related]
8. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Cronise KE; Hernandez BG; Gustafson DL; Duval DL Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548 [TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma. Tagawa M; Tambo N; Maezawa M; Tomihari M; Watanabe KI; Inokuma H; Miyahara K PLoS One; 2020; 15(4):e0232365. PubMed ID: 32330187 [TBL] [Abstract][Full Text] [Related]
10. RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors. Parker HG; Dhawan D; Harris AC; Ramos-Vara JA; Davis BW; Knapp DW; Ostrander EA BMC Cancer; 2020 Mar; 20(1):251. PubMed ID: 32209086 [TBL] [Abstract][Full Text] [Related]
11. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061 [TBL] [Abstract][Full Text] [Related]
12. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma. Mochizuki H; Breen M Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944 [TBL] [Abstract][Full Text] [Related]
13. Characterizing the molecular and immune landscape of canine bladder cancer. Cronise KE; Das S; Hernandez BG; Regan DP; Dailey DD; McGeachan RI; Lana SE; Page RL; Gustafson DL; Duval DL Vet Comp Oncol; 2022 Mar; 20(1):69-81. PubMed ID: 34021685 [TBL] [Abstract][Full Text] [Related]
14. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma. Mochizuki H; Shapiro SG; Breen M PLoS One; 2015; 10(12):e0144170. PubMed ID: 26649430 [TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of the COX2/PGE Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T Sci Rep; 2020 May; 10(1):7826. PubMed ID: 32385388 [TBL] [Abstract][Full Text] [Related]
16. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. Schrempp DR; Childress MO; Stewart JC; Leach TN; Tan KM; Abbo AH; de Gortari AE; Bonney PL; Knapp DW J Am Vet Med Assoc; 2013 Jun; 242(11):1534-8. PubMed ID: 23683018 [TBL] [Abstract][Full Text] [Related]
17. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study. Poirier VJ; Forrest LJ; Adams WM; Vail DM J Am Anim Hosp Assoc; 2004; 40(2):131-6. PubMed ID: 15007049 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in dogs with urinary bladder carcinoma. Rocha TA; Mauldin GN; Patnaik AK; Bergman PJ J Vet Intern Med; 2000; 14(5):486-90. PubMed ID: 11012109 [TBL] [Abstract][Full Text] [Related]
19. Presumptive malignant transformation of chronic polypoid cystitis into an apical transitional cell carcinoma without BRAF mutation in a young female dog. Butty EM; Hahn S; Labato MA J Vet Intern Med; 2021 May; 35(3):1551-1557. PubMed ID: 33739477 [TBL] [Abstract][Full Text] [Related]
20. Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction. Mochizuki H; Shapiro SG; Breen M Vet Pathol; 2016 Jul; 53(4):764-72. PubMed ID: 26574558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]